Toronto Dominion Bank Boosts Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Toronto Dominion Bank lifted its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 11.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,416 shares of the medical research company's stock after acquiring an additional 6,149 shares during the quarter. Toronto Dominion Bank's holdings in IQVIA were worth $14,317,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in IQV. Capital Performance Advisors LLP bought a new stake in shares of IQVIA in the 3rd quarter valued at about $27,000. Park Place Capital Corp acquired a new stake in IQVIA in the third quarter valued at approximately $28,000. Itau Unibanco Holding S.A. purchased a new position in IQVIA in the second quarter worth $29,000. International Assets Investment Management LLC acquired a new position in shares of IQVIA during the second quarter worth $32,000. Finally, Avior Wealth Management LLC lifted its holdings in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock valued at $38,000 after purchasing an additional 87 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Performance

Shares of NYSE:IQV traded down $1.31 during trading on Friday, hitting $199.06. 1,161,543 shares of the stock traded hands, compared to its average volume of 1,186,062. The company has a fifty day moving average price of $212.24 and a two-hundred day moving average price of $224.21. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a market cap of $36.13 billion, a price-to-earnings ratio of 26.12, a P/E/G ratio of 2.07 and a beta of 1.49. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on IQV. JPMorgan Chase & Co. reduced their target price on IQVIA from $279.00 to $240.00 and set an "overweight" rating on the stock in a research report on Tuesday, November 5th. StockNews.com lowered shares of IQVIA from a "buy" rating to a "hold" rating in a research report on Thursday, November 28th. William Blair reissued an "outperform" rating on shares of IQVIA in a research report on Wednesday. The Goldman Sachs Group cut their price target on shares of IQVIA from $280.00 to $250.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Finally, TD Cowen lowered their price objective on shares of IQVIA from $270.00 to $255.00 and set a "buy" rating for the company in a research note on Friday, November 1st. Four research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $256.19.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.